Article Text

PDF
Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI

Statistics from Altmetric.com

E Erdmann

Dr E Erdmann, Universität zu Köln, Köln, Germany; erland.erdmann@uni-koeln.de

STUDY DESIGN

Design:

subgroup analysis of a randomised controlled trial (PROspective pioglitAzone Clinical Trial In macroVascular Events [PROactive]).

Allocation:

{concealed}*.†

Blinding:

blinded {patients, investigators, and study personnel}*.†

STUDY QUESTION

Setting:

19 European countries.

Patients:

subgroup of 2445 patients with type 2 diabetes (age range 35–75 y, 74% men, 99% white), myocardial infarction (MI) ⩾6 months before randomisation, {and a haemoglobin A1c concentration >6.5% (or local equivalent)}*.

Intervention:

pioglitazone (n = 1230), increased in 15 mg steps from 15 mg to 45 mg over 2 months to maximum tolerable dose, or matching placebo (n = 1215).

Outcomes:

composite end points for the subgroup analysis were fatal or non-fatal MI, cardiovascular (CV) death or non-fatal MI, and CV death or non-fatal MI …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.